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Genome-wide response to antihypertensive medication 
using home blood pressure measurements: a pilot 
study nested within the HOMED-BP study
Only one-fourth of hypertensive patients take 
sufficient blood pressure control [1], this is 
because of inaccurate evaluation of blood pres-
sure, inappropriate selection of antihypertensive 
drugs and poor patients’ adherence to antihy-
pertensive drug therapy [2]. Genetic factors also 
influence blood pressure elevation and response 
to antihypertensive medication [3]. To lead to 
personalized medicine based on genetic infor-
mation, a genome-wide approach is desired 
in pharmaco genomics studies [4]. However, 
few studies have provided information on the 
response of crucial genes to various antihyper-
tensive drugs by a comprehensive genome-wide 
association study (GWAS) approach [5–7].
Self-measurement of blood pressure at home 
using automated devices offers a greater num-
ber of readings that are free from observer bias. 
The home blood pressure measurement provides 
higher diagnostic accuracy compared with con-
ventional office blood pressure measurement [8,9]. 
However, no previous pharmaco genomics study 
has assessed antihypertensive drug effect based 
on repeated home blood pressure measurements.
We carried out a GWAS in patients participat-
ing in the HOMED-BP study [10], a randomized 
controlled drug-intervention trial evaluating car-
diovascular outcome based on home blood pres-
sure measurement. In the present study, we aim 
to elucidate the genetic background underlying 
responsiveness to three major antihypertensive 
drugs, calcium channel blockers (CCBs), angio-
tensin-converting enzyme inhibitors (ACEIs) 
and angiotensin II receptor blocker (ARB).
Methods
 Study protocol
The present HOMED-BP-GENE study is an 
ancillary project of the HOMED-BP study. 
Detailed protocol of the HOMED-BP Study 
has been described previously [10,11]. Briefly, 
patients with mild-to-moderate hypertension 
with a minimum age of 40 years were recruited 
from 457 general practices throughout Japan. 
Treatment naive patients as well as previously 
treated patients, whose antihypertensive drug 
treatment could be discontinued for at least 
2 weeks, qualified for enrolment. Off treatment, 
they had to maintain a home blood pressure of 
135–179 mmHg systolic or 85–119 mmHg dia-
stolic. Eligible patients should have no contra-
indication for antihypertensive agents. Random-
ization was based on a computerized random 
number function with a minimization algorithm 
running on a central server at Tohoku Univer-
sity (Sendai, Miyagi, Japan), considering sex, age 
and the systolic and diastolic levels of the home 
blood pressure. In a 2 × 3 design, eligible patients 
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were randomized to usual versus tight control 
of the home blood pressure and to the initiation 
of antihypertensive drug treatment with CCBs, 
ACEIs or ARBs. Usual control was a home blood 
pressure ranging from 125 to 134 mmHg sys-
tolic and from 80 to 84 mmHg diastolic. Tight 
control was home blood pressure values below 
125 mmHg systolic and below 80 mmHg dia-
stolic. The HOMED-BP protocol is registered 
with the UMIN Clinical Trial Registry, number 
C000000137 [101].
The HOMED-BP-GENE study aimed to 
elucidate the involvement of genetic influence 
focusing on SNPs. Physicians at 12 centers par-
ticipated in the study, and 300 patients among 
476 randomized patients from these centers 
were recruited for the genetic ana lysis. Of those, 
four patients were excluded because of proto-
col violation. Home blood pressure data dur-
ing 10 to 28 days after the drug administration 
in 31 patients were not available or unreliable. 
Therefore, a total of 265 patients were ana-
lyzed in the present study (Supplementary Figure 1; 
www.futuremedicine.com/doi/suppl/10.2217/
pgs.13.161). Owing to a bug in the electronic 
randomization, some patients were initially 
assigned to ARBs instead of ACEIs. In the 
pilot phase of the overall HOMED-BP study, 
this problem was identified and corrected, so 
that randomization became balanced. Because 
the patients included in the GWAS study were 
among those recruited early, there remains a 
shortfall in the number of patients randomized 
to ACEIs. All 265 patients analyzed patients 
took only a single antihypertensive agent dur-
ing the period covered by the GWAS. Baseline 
characteristics of the 265 analyzed patients and 
211 who did not take part in the GWAS project 
were similar (p ≥ 0.083) except for age (61.5 vs 
59.6 years; p = 0.033) and baseline systolic pres-
sure (148.8 vs 152.2 mmHg; p = 0.0039). The 
study complies with the Declaration of Helsinki, 
and the study protocol was approved by the insti-
tutional review boards of Osaka University and 
Tohoku University, Japan. All study participants 
gave their written informed consent.
 Evaluation of blood pressure 
changes
Patients received spoken and written instructions 
on blood pressure self-measurement and the uti-
lized the validated [12] oscillometric OMRON 
HEM 747IC-N devices (Omron Healthcare Co., 
Ltd., Kyoto, Japan). They were asked to measure 
blood pressure and heart rate after 2 min of rest 
in a sitting position every morning throughout 
the whole study. They had to obtain these mea-
surements within 1 h of waking up, before break-
fast and before taking their antihypertensive 
medication. The device stores up to 350 readings 
in its memory. The home blood pressure values 
stored in the memory were uploaded via a local 
computer to the server at Tohoku University at 
each visit. These values were automatically calcu-
lated by the server and immediately displayed on 
the screen of the local computer in the practices 
along with an advice for treatment adjustment 
based on a computerized algorithm running on 
the central server.
Data on home morning blood pressure for 
5 days before randomization and for 5 days 
after 10 to 28 days of randomized drug treat-
ment were averaged separately. We used this 
time window for the following reasons: the home 
blood pressure used for determining eligibility 
and treatment adjustments at each visit in the 
HOMED-BP study was the average of the morn-
ing readings available over 5 days immediately 
preceding the visit [10,11]; the clinical investiga-
tors followed the study participants at intervals 
of approximately 2–4 weeks in general practice 
and 4–8 weeks at hospital outpatient clinics; and 
the time intervals needed to attain the maximum 
antihypertensive effects of losartan 50 mg, can-
desartan 8 mg, telmisartan 40 mg and olmesar-
tan 20 mg on the morning blood pressure were 
22.8, 11.0, 8.9 and 9.2 days, respectively [13]. In 
the genetic ana lysis, blood pressure response was 
calculated using the difference between these 
two periods. Differences in systolic and diastolic 
home blood pressure were analyzed individually.
 Replication study – GEANE study
The GEANE study is a multicenter clinical trial 
registered in Japan (UMIN Clinical Trial Regis-
try number C000000119 [101]), which utilized an 
open random crossover protocol to examine the 
antihypertensive effects of amlodipine (CCB, 
5 mg/day), valsartan (ARB, 80 mg/day), and a 
thiazide-like diuretic indapamide (2 mg/day). 
After the written informed consent was approved 
by the ethical review committee of the National 
Cerebro- and Cardiovascular Research Center 
(Suita, Japan) and other collaborated institutes, 
order of drug prescription for each patient was 
decided by the automatic randomization system 
in the GEANE study administrative office. For 
the replication study of CCB- or ARB-respon-
sive SNPs in the HOMED-BP-GENE study, we 
used 79 untreated patients in the GEANE study 
with essential hypertension of systolic office 
blood pressure ranging from 140 to 179 mmHg 
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and/or diastolic office blood pressure from 90 to 
109 mmHg. Each assigned drug was prescribed 
for 3 months, starting at one half of the final 
dose and increasing to the regular dose. Home 
blood pressure was measured twice per day at 
home, and average values of 3 consecutive days 
before the randomization and at the end of each 
drug administration period, respectively, were 
used for the ana lysis. Blood samples at baseline 
were collected for checking basal medical status 
and genetic analyses.
 Genetic ana lysis
Genomic DNA was isolated from peripheral 
blood leukocytes and extracted from 200 ml of 
buffy coat using a QIAamp® DNA Blood Kit 
(Qiagen Inc., Hilden, Germany). All samples 
in the HOMED-BP-GENE study were geno-
typed by BIOMATRIX RESEARCH Co. Ltd. 
(Nagareyama, Chiba, Japan) with the Genome-
Wide Human Mapping 500K SNPs Micro array 
(Affymetrix Genome Wide Human Array 5.0: 
Affymetrix, Inc. CA, USA) according to the 
manufacturer’s instructions. Of the 443,816 
SNPs on the array set, the number of SNPs 
suitable for the ana lysis was reduced to 298,046 
(67.16%) for the following reasons (in order): 
were on the sex chromosome (n = 10,288), 
minor allele frequency <5% (n = 121,183), no 
call rate >10% across samples (n = 8028) and 
deviation from Hardy–Weinberg equilibrium 
p-value (<0.01; n = 6271).
Samples in the GEANE study were geno-
typed with the same Affymetrix Genome Wide 
Human Array 5.0 at the Research Institute of the 
National Cerebro- and Cardiovascular Research 
Center.
 Statistical analyses
We used SAS software, version 9.3 (SAS Insti-
tute, NC, USA), for database management and 
basic statistical ana lysis. We also used JMP 
Genomics, version 6.0 (SAS Institute), for the 
phenotype–genotype ana lysis. For comparison 
of means and proportions, we applied the Z test 
for large samples and the c2 statistic, respec-
tively. The genetic ana lysis was conducted for 
a trend-based and a genotype-based analyses 
at each SNP locus with covariate adjustment 
for age, sex, BMI, diabetes mellitus, the home 
blood pressure level before randomization, aver-
age duration after taking the treatment, and 
the defined daily doses (DDDs) of each drug 
[10,14,102]. DDD is the average maintenance dose 
per day for a drug administrated in its main 
indication [102].
We considered a p-value of <10-5 as a statis-
tically acceptable level based on the previous 
GWAS by the Wellcome Trust Case Control 
Consortium (WTCCC [15]), in which the same 
DNA microarray was used as in the present 
study [15]. We also reported association between 
blood pressure response and SNPs with p-values 
from 10-4 and 10-5. In the GEANE replication 
study, we performed similar trend-based and 
genotype-based analyses for SNP locus with 
covariate adjustment for age, sex, BMI and home 
blood pressure level before randomization. We 
did not conduct the replication study for SNPs 
associated with an ACEI response because the 
GEANE study did not include patients with an 
ACEI prescription.
Results
Patient characteristics in all analyzed subjects 
are shown in table 1. Although the number of 
patients in the ACEI group (n = 71), was smaller 
than those in CCB and ARB groups (n = 93 and 
101, respectively), baseline characteristics before 
treatment did not differ among the three drug 
groups (p ≥ 0.075) with the exception of age 
(p = 0.0074).
Home blood pressure responses in the 
ACEI group were significant but small (sys-
tolic: -3.7 ± 9.9 mmHg, p = 0.0022; dia-
stolic: -2.4 ± 6.0 mmHg, p = 0.0014) com-
pared with those in the CCB group (systolic: 
-9.4 ± 10.4 mmHg, p < 0.0001; diastolic: 
-4.1 ± 6.2 mmHg, p < 0.0001) and in the ARB 
group (systolic: -7.8 ± 10.3 mmHg, p < 0.0001; 
diastolic: -3.6 ± 5.5 mmHg, p < 0.0001). Figure 1 
& Supplementary Figure 2 show Manhattan plots from 
the GWAS indicating associations between 
298,046 SNPs and home blood pressure response 
to CCB, ACEI and ARB using trend tests (Fig-
ure 1) and genotype tests (Supplementary Figure 2), 
respectively. Of those, 16 SNPs and 284 SNPs 
were associated with the antihypertensive effect 
for home blood pressure by CCB, ACEI or ARB 
with p-value less than 10-5 and 10-4, respectively 
(Supplementary tableS 1 & 2).
Clinical baseline characteristics of the 
79 GEANE replication study participants are 
shown in Supplementary table 3. No significant treat-
ment effect as well as carry-over effect and period 
effect were detected in any of the three drug arms 
for home blood pressure (p = 0.14, 0.98 and 0.53 
for systolic pressure; p = 0.49, 0.92 and 0.85 for 
diastolic pressure, respectively). Including those 
with marginal significance (p < 0.10), replicated 
SNPs associated with drug response are shown in 
table 2. Six associated gene polymorphisms were 
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further analyzed for blood pressure reduction 
by corresponding antihypertensive drug classes 
(table 3). As a representative, two tightly linked 
SNPs, rs1283807 and rs704209 (Supplementary 
Figure 3), are located in the intron of ABCC9, and 
systolic home blood pressure response to ARB was 
significantly different among the three genotypes 
in rs1283807, G/G (-12.7 ± 9.1 mmHg), A/G 
(-8.2 ± 9.3 mmHg) and A/A (+2.1 ± 9.7 mmHg). 
Other associated genes for systolic blood pressure 
response were PICALM by tightly linked SNPs 
(rs588076 and rs597446; Supplementary Figure 4) 
and TANC2. Those for diastolic blood pressure 
response were YIPF1 by completely linked SNPs 
(rs6680026 and rs6588492; Supplementary Figure 5), 
NUMA1 and APCDD1.
We carried out a sensitivity ana lysis including 
all morning blood pressure measurements avail-
able from 10 to 28 days after the randomization. 
These results were confirmatory.
Discussion
This study is the first GWAS with replication 
to clarify the SNPs susceptible to the antihyper-
tensive effects of CCBs, ACEIs and ARBs using 
repeated home blood pressure measurements. 
In consequence, SNPs in PICALM, TANC2, 
NUMA1 and APCDD1 are associated with CCB 
responses and those in ABCC9 and YIPF1 are 
associated with ARB responses.
Previously, there was no genome-wide 
pharmaco genomic study for the effect of anti-
hypertensive drugs using home blood pressure 
measurements. Repeated home blood pres-
sure measurements are more accurate than 
conventional blood pressure measurements 
[8,9]. The reproducibility of home blood pres-
sure, defined as the difference between the 
initial 5-day average (4–8 days) and the last 
5-day average (17–21 days), was -1.9 ± 7.0 
(mean ± standard deviation) mmHg for systolic 
Table 1. Characteristics of HOMED-BP-GENE participants.
Characteristic CCBs ACEIs ARBs
Number 93 71 101
Mean characteristic, mean (SD) 
Age (years) 59.6 (9.7) 60.7 (8.9) 63.7 (9.5)
BMI (kg/m2) 24.8 (3.1) 25.0 (3.1) 24.5 (3.0)
Home measurements before treatment, mean (SD)
– Systolic pressure (mmHg) 148.9 (13.9) 149.3 (11.4) 148.3 (12.2) 
– Diastolic pressure (mmHg) 89.7 (9.9) 89.7 (9.3) 86.8 (10.4) 
– Heart rate (bpm) 67.1 (8.6) 67.1 (8.5) 67.4 (9.8) 
Home measurements after drugs, mean (SD) 
– Systolic pressure (mmHg) 139.5 (12.7) 145.5 (13.7) 140.5 (14.8) 
– Diastolic pressure (mmHg) 85.6 (9.3) 87.3 (10.3) 83.1 (10.2) 
– Heart rate (bpm) 68.5 (8.4) 66.1 (9.0) 68.2 (11.0) 
Biochemical measurements, mean (SD) 
– Plasma glucose (mmol/l) 5.9 (1.7) 5.8 (0.9) 5.9 (1.3) 
– Serum total cholesterol (mmol/l) 5.3 (0.8) 5.3 (0.9) 5.4 (0.8) 
Number with characteristic, proportion (%) 
Women 53 (57.0) 37 (52.1) 53 (52.5) 
Current smoking 19 (20.4) 13 (18.3) 19 (19.0) 
Habitual drinking 48 (51.6) 37 (52.1) 58 (58.0) 
Diabetes mellitus 9 (9.7) 6 (8.5) 18 (17.8) 
Hypercholesterolemia 33 (35.5) 18 (25.4) 32 (31.7) 
Previous cardiovascular disease 5 (5.4) 4 (5.6) 7 (6.9) 
Home measurements are the average of the morning readings over 5 days immediately preceding the clinic visit. Diabetes 
mellitus is defined as a fasting plasma glucose level of 7.0 mmol/l (126 mg/dl) or more, or a HbA1c level of 6.5% or more, 
or treatment with oral antidiabetic drugs or insulin. Hypercholesterolemia is defined as a total cholesterol level of 
5.69 mmol/l (220 mg/dl) or more, a history of hypercholesterolemia or taking lipid-lowering drugs. Baseline characteristics 
before treatment did not differ among three drug groups (p ≥ 0.075) with the exception of age (p = 0.0074).  
ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; bpm: Beats per minute;  
CCB: Calcium channel blocker; SD: Standard deviation.
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and -1.4 ± 4.8 mmHg for diastolic, respectively, 
among 172 patients from a general population in 
Ohasama, Japan [16]. In the clinical setting, the 
corresponding difference among 42 patients with 
placebo administration was 1.1 ± 6.2 mmHg 
for systolic and 0.2 ± 5.7 mmHg for diastolic, 
respectively [16]. Thus, the home blood pressure 
measurement is highly reproducible and shows 
that there is minimal, possible no, placebo effect. 
Compared with conventional blood pressure, we 
require a smaller number of subjects to evaluate 
the antihypertensive effect of a drug treatment 
based on home blood pressure [16].
Turner and colleagues investigated the blood 
pressure response to candesartan by validat-
ing opposite direction associations with the 
response to hydrochlorothiazide [7]. Based on 
a case–control sampling design, each of the 
300 white patients (in Rochester, MN, USA) 
and 300 black patients (in Atlanta, GA, USA) 
who were treated with candesartan were divided 
into three groups according to their diastolic 
blood pressure responses, and mid-tertiles were 
eliminated (102 white patients and 107 black 
patients, respectively). Turner and colleagues 
carried out the primary genome-wide associa-
tion analyses of categorically defined good ver-
sus poor blood pressure response to candesar-
tan. By SNP p-values <10-4, they identified 285 
SNPs in white patients and 272 SNPs in black 
patients that were associated with the response 
to candesartan. They identified six SNPs that 
had the most significant opposite direction 
associations with blood pressure response to 
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Figure 1. Manhattan plots showing genome-wide association results of SNPs with home blood pressure response to a 
calcium channel blocker, angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. (A) Calcium channel 
blocker, (B) angiotensin-converting enzyme inhibitor and (C) angiotensin II receptor blocker. The p-values for the 298,046 SNPs on 
autosomes obtained using trend tests in systolic (left panels) and diastolic (right panels) home blood pressure. The horizontal dashed line 
indicates the threshold of p < 10-4. 
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hydrochlorothiazide (i.e., one-sided p < 0.05), 
but only from 273 of the 285 SNPs in white 
patients because the c2 test statistic in black 
patients showed nonsignificant results for the 
associations. Those in the chromosome 11q21 
region were the most significantly associated 
with response to candesartan in white patients, 
had the strongest opposite direction associations 
with response to hydrochlorothiazide and had 
the same direction associations with response 
to candesartan in the 193 black patients. Their 
approach, however, does not wholly substanti-
ate the conclusions. First, they analyzed only 
diastolic blood pressure response, not systolic 
pressure. Second, no rationale was found why 
they eliminate the mid-tertiles of blood pressure 
response in a categorical ana lysis, this could have 
resulted in the loss of information. Finally, there 
is little evidence as to whether or not the oppo-
site direction blood pressure response to ARB, 
candesartan and diuretic hydrochlorothiazide 
would be observed in clinical practice.
PICALM, also known as CALM, is involved 
in clathrin-mediated endocytosis and is ubiqui-
tously expressed in all tissues [17,18]. SNPs in the 
PICALM gene were reported to be significantly 
associated with Alzheimer’s disease. [18,19]. The 
role of PICALM in the pathogenesis of Alzheim-
er’s disease could be explained through the fol-
lowing: a possible role of clathrin-mediated 
endocytosis in internalization and recycling 
of full length amyloid precursor protein [19]; 
PICALM’s role in synaptic vesicle formation; 
reduction of synaptic density and memory loss 
in Alzheimer’s disease [20]; and dendritic dys-
trophy and disrupted endocytosis and secre-
tion of neurotransmitters owing to PICALM 
reduction as seen in cell culture [21]. Based on 
the established association of late-onset Alz-
heimer’s disease with the e4 variant of APOE 
[22], Sweet and colleagues reported that genetic 
variation in PICALM was also associated with 
lower age at midpoint of cognitive decline in 
models that included apolipoprotein E [23]. From 
the double-blind, placebo-controlled Syst-Eur 
trial, blood pressure lowering therapy initiated 
with nitrendipine, a long-acting CCB, protects 
against dementia in older hypertensive patients 
[24,25]. The protective effect of CCB for cognitive 
function might be mediated by gene variations, 
including PICALM.
Although marginally replicated, two SNPs 
in ABCC9 (rs704209 and rs1283807) showed 
strong association with the response to ARB. 
ABCC9 encoded ATP-sensitive potassium chan-
nels are characterized by inhibition of channel 
opening when the ATP concentration at the 
cytoplasmic cell surface is increased. ABCC9 
is highly expressed in skeletal muscle and the 
heart and regulates ATP-sensitive potassium 
channels [26]. Inagaki and colleagues noted 
that sulfonylureas, substances widely used as 
oral hypoglycemic agents in the treatment 
of noninsulin-dependent diabetes mellitus, 
inhibits the activity of potassium channels [27]. 
They cloned ABCC9 known as an isoform of a 
sulfonylurea receptor, designated sulfonylurea 
receptor-2, from a rat brain cDNA library [28]. 
Genetic mutations of ABCC9 are reported to 
be one of the causes in dilated cardiomyopathy 
[29] and familial atrial fibrillation [30]. From the 
meta-ana lysis based on 11 randomized con-
trolled trials, Healey and colleagues reported 
that ARB as well as ACEI has a protective 
effect beyond blood pressure reduction for atrial 
fibrillation [31]. For ACEI, this effect was most 
clearly observed in patients with left ventricular 
dysfunction [32] and clinical heart failure [33]. 
Although detailed mechanisms of ABCC9 con-
nected to the anti hypertensive effects of ARBs 
are unclear and no previous study reported 
on the association between ABCC9 and the 
renin–angiotensin system, genetic alteration 
by SNPs in ABCC9 may inf luence on the 
 pharmacological action of ARBs.
Recent findings by Shimomura and colleagues 
demonstrated that APCDD1 could regulate a 
diversity of biological processes controlled by 
Wnt signaling [34]. Wnt signaling is involved in 
heart development and is reported to be acti-
vated in cardiac hypertrophy and cardiomyopa-
thy [35,36]. In vitro, Wnt-5a effect on field excit-
atory postsynaptic potentials in hippocampal 
slices was blocked by nifedipine [37]. APCDD1 
polymorphisms might affect the electrophysi-
ological activity of the heart, although it remains 
conjectural.
To the best of our knowledge, the current 
study is the first report to demonstrate the 
clinical importance of two SNPs in YIPF1 
(rs6588492 and rs6680026) that are associated 
with ARB response. These SNPs were strongly 
associated in the HOMED-BP population 
(p ≤ 4.23 × 10-5) and also significantly replicated 
for both genotype and trend associations in the 
GEANE population (p ≤ 0.015). There is only 
one report regarding the TANC2 gene. The cod-
ing protein TANC2 is differentially expressed in 
postmortem brains from patients with atypical 
cases of frontotemporal lobar degeneration, but 
the metabolism of TANC2 is unknown [38]. The 
NUMA1 gene maps to chromosome 11q13 [39], 
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a region commonly amplified in ovarian cancer 
[40], and NUMA is found to be highly expressed 
in epithelial ovarian cancers [41]. However, no 
studies have tried to indicate the association 
between antihypertensive medication and these 
gene polymorphisms. 
SNPs associated with ARBs and those with 
ACEIs are different (Supplementary tableS 1 & 2). 
The present study revealed that some SNPs 
might affect drug efficacy of ACEIs, although 
no replication study has been conducted. As a 
representative, rs548987 in the SLC17A3 gene 
was significantly associated with the changes of 
systolic home blood pressure by ACEIs. 
The present study must be interpreted within 
the context of its potential limitations. First, we 
analyzed only 265 Japanese patients. Second, 
our study is likely to be underpowered: we ran 
sample size calculations using the SAS Power and 
Sample Size software, version 3.1 (SAS Institute), 
to detect a 10-mmHg difference in the blood 
pressure responses to drug treatment between 
two alleles in a single SNP with a significance 
of 1.678 × 10-7, which is Bonferroni’s correction 
threshold for multiple testing, 235 patients would 
be needed with the power set at 80% and a minor 
allele frequency at 40%. For a minor allele fre-
quency of 5%, 1132 patients would be needed. 
On the other hand, several SNPs associated with 
the responses to antihypertensive drugs were rep-
licated at the p-value level <10-5–10-4. Third, pro-
tocols of the HOMED-BP-GENE and GEANE 
studies differed. Individual drug information was 
summarized as the DDD index in the HOMED-
BP-GENE study, whereas specific drugs, valsartan 
and amlodipine, were prescribed in the GEANE 
study. Fourth, because of the limited number of 
patients, we could not run categorical analyses, 
for instance by age group. We considered running 
an additional sensitivity ana lysis using only home 
blood pressure data measured during the fourth 
week after randomization (22–28 days). How-
ever, because the number of analyzable patients 
decreased from 265 to 144 (50 for CCBs and 60 
for ARBs), this sensitivity ana lysis proved to be 
impracticable. Finally, we could not conduct the 
replication study for the ACEI responders.
Future perspective
The HOMED-BP-GENE study breaks new 
ground for assessing antihypertensive effects 
based on high-fidelity phenotyping by self- 
measured home blood pressure. We demon-
strated a catalog of susceptible SNPs for the 
blood pressure response to CCBs, ACEIs and 
ARBs based on the GWAS. Pharmacogenomic 
approaches should be based on rigid phenotype 
information, and our approach based on self-
measured home blood pressure could be widely 
accepted even in the next generation of genom-
ics. We reported that a 13.2 mmHg reduction 
of systolic home pressure, compared with the 
14.8 mmHg difference that we observed in the 
reduction between the ABCC9 G/G versus A/A 
polymorphism, would prevent 47% of cardio-
vascular end points [10]. Information from the 
HOMED-BP-GENE study may be useful to 
help realize the prediction of the best drug for 
individual patients based on genetic information 
in the personalized treatment of hypertension.
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Executive summary
Background
  The aim of this study was to investigate the influence of genetic factors on blood pressure elevation and response to antihypertensive 
medication. In order to achieve personalized medicine based on genetic information, the genome-wide approach is desired in 
pharmacogenomics studies.
  Based on the multicenter HOMED-BP study, in which antihypertensive drug treatment based on home-measured blood pressure has 
proven to be feasible, we aim to elucidate the genetic background underlying responsiveness to antihypertensive drugs.
Methods
  We recruited 265 patients who completed the genomic study.
  Home blood pressure was measured for 5 days off-treatment before randomization and for 5 days after 2–4 weeks of randomized 
drug treatment. Genotyping was performed by 500K DNA microarray chips. The blood pressure responses to the three drugs were 
analyzed as a quantitative trait.
  For replication of SNPs, we used the multicenter GEANE study, in which patients were randomized to valsartan or amlodipine.
Results
  Six associated gene polymorphisms, four with calcium channel blocker (CCB) responses and two with angiotensin II receptor blocker 
(ARB) responses, were identified with significant replication.
Conclusion
  This study is the first report of a genome-wide association study about the antihypertensive drug responses of CCBs, ACE inhibitors 
and ARBs.
  Our findings, the first based on high-fidelity phenotyping by home blood pressure measurement, which provides higher diagnostic 
accuracy compared with conventional office blood pressure measurement, potentially identified susceptible SNPs for the blood pressure 
response to CCBs and ARBs.
  Information from the present study may be useful to realize the prediction of the best drug based on genetic information in the 
personalized treatment of hypertension.
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